Methods and compositions for the treatment of gastrointestinal disorders
DCFirst Claim
1. A purified peptide consisting of the amino acid sequence:
- Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO;
31) or a pharmacologically acceptable salt thereof.
4 Assignments
Litigations
0 Petitions
Accused Products
Abstract
The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn'"'"'s disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation (post-operative ileus), and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
63 Citations
70 Claims
-
1. A purified peptide consisting of the amino acid sequence:
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO;
31) or a pharmacologically acceptable salt thereof.- View Dependent Claims (7, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)
-
2. A purified peptide consisting of the amino acid sequence:
- Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO;
31).
- Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO;
-
3. A pharmacologically acceptable salt of a purified peptide consisting of the amino acid sequence:
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO;
31).
-
4. A purified peptide comprising the amino acid sequence:
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO;
31) or a pharmacologically acceptable salt thereof, wherein the peptide activates the guanylate cyclase C receptor.
-
5. A purified peptide comprising the amino acid sequence:
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO;
3
1), wherein the peptide activates the guanylate cyclase C receptor.
-
6. A pharmacologically acceptable salt of a purified peptide comprising the amino acid sequence:
- Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO;
31), wherein the peptide activates the guanylate cyclase C receptor.
- Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO;
-
8. A pharmaceutical composition comprising:
-
(a) a purified peptide consisting of the amino acid sequence;
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO;
31) or a pharmacologically acceptable salt thereof; and(b) a pharmaceutically acceptable carrier or excipient.
-
-
9. A pharmaceutical composition comprising:
-
(a) a purified peptide consisting of the amino acid sequence;
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO;
31); and(b) a pharmaceutically acceptable carrier or excipient. - View Dependent Claims (29, 33, 37, 38, 39, 43, 44, 45, 46, 47, 51, 55, 59, 63, 67)
-
-
10. A pharmaceutical composition comprising:
-
(a) a pharmacologically acceptable salt of a purified peptide consisting of the amino acid sequence;
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO;
31); and(b) a pharmaceutically acceptable carrier or excipient. - View Dependent Claims (30, 34, 40, 48, 52, 56, 60, 64, 68)
-
-
11. A pharmaceutical composition comprising:
-
(a) a purified peptide comprising the amino acid sequence;
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO;
31) or a pharmacologically acceptable salt thereof; and(b) a pharmaceutically acceptable carrier or excipient. - View Dependent Claims (49)
-
-
12. A pharmaceutical composition comprising:
-
(a) a purified peptide comprising f the amino acid sequence;
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO;
31); and(b) a pharmaceutically acceptable carrier or excipient. - View Dependent Claims (31, 35, 41, 50, 53, 57, 61, 65, 69)
-
-
13. A pharmaceutical composition comprising:
-
(a) a pharmacologically acceptable salt of a purified peptide comprising the amino acid sequence;
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO;
31); and(b) a pharmaceutically acceptable carrier or excipient. - View Dependent Claims (32, 36, 42, 54, 58, 62, 66, 70)
-
Specification